Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMVN3FU)

Drug Name
CA-074Me Drug Info
Synonyms
147859-80-1; Cathepsin B Inhibitor IV; CA-074 methyl ester; CA-074 Me; Methyl N-({(2s,3s)-3-[(Propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-Isoleucyl-L-Prolinate; CA-074-Me; MFCD03452890; methyl N-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]carbonyl}-L-isoleucyl-L-prolinate; CA 074 methyl ester; CA 074Me; CA074Me; CA inhibitor 6; (S)-methyl 1-((2S,3S)-3-methyl-2-((2S,3S)-3-(propylcarbamoyl)oxirane-2-carboxamido)pentanoyl)pyrrolidine-2-carboxylate; PrNH-tES-Ile-Pro-OMe; epoxysuccinyl derivative 6; KBioGR_000234; KBioSS_000234; CHEMBL262103; SCHEMBL1974424; BDBM16503; KBio2_000234; KBio2_002802; KBio2_005370; KBio3_000467; KBio3_000468; DTXSID50881386; Bio2_000234; Bio2_000714; HMS1361L16; HMS3886D15; EX-A1196; ZINC4899858; s7420; CCG-268623; CS-6086; DB07223; CA-074 methyl ester (CA-074 Me); IDI1_033984; NCGC00163431-01; AC-32670; methyl (2S)-1-[(2S,3S)-3-methyl-2-[[(2S,3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylate; methyl (2S)-1-[(2S,3S)-3-methyl-2-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]formamido}pentanoyl]pyrrolidine-2-carboxylate; QC-10413; HY-100350; 859C801; Q27096448; (L-3-trans-(Propylcarbamyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester; CA074ME; N-(L-3-TRANS-PROPYLCARBAMOYLOXIRANE-2-CARBONYL)-L-ISOLEUCYL-L-PROLINE METHYL ESTER
Cross-matching ID
PubChem CID
6610318
ChEBI ID
CHEMBL262103
CAS Number
CAS 147859-80-1
TTD Drug ID
D9MT4S

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ferroptosis 2.20 0.00e+0 36/41 (87.8%) HMOX1;GCLM;SLC7A11;...
Protein processing in endoplasmic reticulum 2.19 0.00e+0 127/171 (74.27%) HSPA1A;HSPA8;HSPA6;...
Legionellosis 2.14 0.00e+0 51/57 (89.47%) HSPA1A;HSPA8;HSPA6;...
Prion disease 1.81 4.04e-2 209/273 (76.56%) HSPA1A;HSPA8;HSPA6;...
Longevity regulating pathway 1.80 3.80e-2 90/151 (59.6%) HSPA1A;HSPA8;HSPA6;...
Base excision repair -1.75 3.52e-2 29/33 (87.88%) POLD2;PARP3;FEN1;...
Drug metabolism -1.75 4.23e-2 78/151 (51.66%) CYP2D6;GSTM1;IMPDH1;...
Citrate cycle (TCA cycle) -1.82 2.91e-2 30/30 (100%) SDHD;DLAT;DLST;...
Protein digestion and absorption -1.83 3.52e-2 78/103 (75.73%) ELN;COL18A1;COL4A4;...
Intestinal immune network for IgA production -1.91 1.58e-2 38/48 (79.17%) CCR9;CD80;IL2;...
Retinol metabolism -1.95 1.06e-2 41/68 (60.29%) UGT2B28;CYP1A2;CYP3A5;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 12.5uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H